Diaceutics (DXRX) full year 2021 results presentation March 2022

Mar 23, 2022

Ask episode

Chapters

Transcript

Episode notes

Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. Diaceutics who are a diagnostic commercialisation company for precision testing, have transitioned to a recurring revenue model, and progressed further in the period than anticipated at the beginning of the year. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m. Going forward they are focused on expanding their service offering, partner network and data repository to serve the diagnostic commercialisation needs both within and outside of oncology.

Peter Keeling, Founder & CEO
00:17 – Introduction
01:59 – Overview of Diaceutics
02:54 – Overview of the period
04:37 – A transformative year
07:17 – Strategic roadmap
08:18 – Customer needs
09:38 – DXRX Platform
10:16 – Our products
11:34 – Our data
12:24 – Why Diaceutics wins
13:41 – ESG

Nick Roberts, CFO
14:47 – Financial KPIs
16:53 – Income statement
18:01 – Revenue and margin growth
20:19 – Cash position
22:38 – Transition of business

Peter Keeling, Founder & CEO
23:33 – Why invest in Diaceutics
24:30 – Outlook

Diaceutics PLC is a United Kingdom-based diagnostic commercialization company. The principal activity of the Company is data analytics and implementation services. The Company is engaged in research and development activities in drug development science, testing data and software platform development. The Company's implementation services include test standardization, test quality assessment, laboratory tech support and others. The Company has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The Company provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.